Annals of Hematology

, Volume 88, Issue 7, pp 607–611 | Cite as

Meeting report: Vienna 2008 Workshop of the German–Austrian Working Group for Studying Prognostic Factors in Myelodysplastic Syndromes

  • Peter Valent
  • Wolf-Karsten Hofmann
  • Guntram Büsche
  • Karl Sotlar
  • Hans-Peter Horny
  • Detlef Haase
  • Torsten Haferlach
  • Wolfgang Kern
  • Peter Bettelheim
  • Christian Baumgartner
  • Wolfgang R. Sperr
  • Thomas Nösslinger
  • Friedrich Wimazal
  • Aristoteles A. Giagounidis
  • Michael Lübbert
  • Otto Krieger
  • Hans-Jochem Kolb
  • Reinhard Stauder
  • Michael Pfeilstöcker
  • Norbert Gattermann
  • Christa Fonatsch
  • Carlo Aul
  • Ulrich Germing
Original Article

Abstract

Criteria, scoring systems, and treatment algorithms for myelodysplastic syndromes (MDS) have been updated repeatedly in recent years. This apparently results from increased awareness and early recognition of the disease, an increasing number of new diagnostic and prognostic markers and tools, and new therapeutic options that may change the course and thus prognosis in MDS. To address these challenges and to create useful new diagnostic and prognostic parameters and scores, the German–Austrian Working Group for Studying Prognostic Factors in MDS was established in 2003 and later was extended to centers in Switzerland (D-A-CH group). In addition, the group cooperates with the European LeukemiaNet, the MDS Foundation, and other national and international working groups in order to improve diagnosis and prognostication. The current article represents a meeting report from the latest workshop organized by the group in Vienna in October 2008.

Keywords

Myelodysplastic syndromes Criteria Prognostication Standardization MDS registry 

Notes

Acknowledgement

Our activities are supported by the German Kompetenznetz Akute und chronische Leukämien of the “Bundesministerium für Bildung und Forschung.”

References

  1. 1.
    Valent P, Horny HP, Bennett JM et al (2007) Definitions and standards in the diagnosis and treatment of the myelodysplastic sydromes: consensus statements and report from a working conference. Leuk Res 31:727–736 doi:10.1016/j.leukres.2006.11.009 PubMedCrossRefGoogle Scholar
  2. 2.
    Bennett JM (2000) World Health Organization classification of the acute leukemias and myelodysplastic syndrome. Int J Hematol 72:131–133PubMedGoogle Scholar
  3. 3.
    Brunning R, Orazi A, Germing U et al (2008) Myelodysplastic syndromes/neoplasms, overview. In: Swerdlow S (ed) WHO classification of tumours of haematopoietic and lymphoid tissues. IARC, Lyon, pp 88–107Google Scholar
  4. 4.
    Bennett JM, Catovsky D, Daniel MT et al (1982) Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51:189–199PubMedGoogle Scholar
  5. 5.
    Horny HP, Sotlar K, Valent P (2007) Diagnostic value of histology and immunohistochemistry in myelodysplastic syndromes. Leuk Res 31:1609–1616 doi:10.1016/j.leukres.2007.05.010 PubMedCrossRefGoogle Scholar
  6. 6.
    Buesche G, Teoman H, Wilczak W et al (2008) Marrow fibrosis predicts early fatal marrow failure in patients with myelodysplastic syndromes. Leukemia 22:313–322 doi:10.1038/sj.leu.2405030 PubMedCrossRefGoogle Scholar
  7. 7.
    Schmitt-Graeff A, Mattern D, Köhler H, Hezel J, Lübbert M (2000) Myelodysplastic syndromes (MDS). Aspects of hematopathologic diagnosis. Pathologe 21:1–15 doi:10.1007/s002920050001 PubMedCrossRefGoogle Scholar
  8. 8.
    Haase D, Germing U, Schanz J et al (2007) New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 110:4385–4395 doi:10.1182/blood-2007-03-082404 PubMedCrossRefGoogle Scholar
  9. 9.
    Steidl C, Steffens R, Gassmann W et al (2005) Adequate cytogenetic examination in myelodysplastic syndromes: analysis of 529 patients. Leuk Res 29:987 doi:10.1016/j.leukres.2005.01.019 PubMedCrossRefGoogle Scholar
  10. 10.
    Haferlach T, Rieder H, Lillington DM et al (2007) Proposals for standardized protocols for cytogenetic analyses of acute leukemias, chronic lymphocytic leukemia, chronic myeloid leukemia, chronic myeloproliferative disorders, and myelodysplastic syndromes. Genes Chromosomes Cancer 46:494–499 doi:10.1002/gcc.20433 PubMedCrossRefGoogle Scholar
  11. 11.
    List A, Kurtin S, Roe DJ et al (2005) Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 352:549–557 doi:10.1056/NEJMoa041668 PubMedCrossRefGoogle Scholar
  12. 12.
    Giagounidis AA, Germing U, Strupp C et al (2005) Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup. Ann Hematol 84:569–571 doi:10.1007/s00277-005-1054-0 PubMedCrossRefGoogle Scholar
  13. 13.
    Rüter B, Wijermans P, Claus R, Kunzmann R, Lübbert M (2007) Preferential cytogenetic response to continuous intravenous low-dose decitabine (DAC) administration in myelodysplastic syndrome with monosomy 7. Blood 110:1080–1082 doi:10.1182/blood-2007-03-080630 PubMedCrossRefGoogle Scholar
  14. 14.
    Raj K, John A, Ho A et al (2007) CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidine. Leukemia 21:1937–1944 doi:10.1038/sj.leu.2404796 PubMedCrossRefGoogle Scholar
  15. 15.
    Knipp S, Hildebrand B, Kündgen A et al (2007) Intensive chemotherapy is not recommended for patients aged >60 years who have myelodysplastic syndromes or acute myeloid leukemia with high-risk karyotypes. Cancer 110:345–352 doi:10.1002/cncr.22779 PubMedCrossRefGoogle Scholar
  16. 16.
    Nolte F, Hofmann WK (2008) Myelodysplastic syndromes: molecular pathogenesis and genomic changes. Ann Hematol 87:777–795 doi:10.1007/s00277-008-0502-z PubMedCrossRefGoogle Scholar
  17. 17.
    Várkonyi J, Demeter J, Tordai A, Andrikovics H (2006) The significance of the hemochromatosis genetic variants in multiple myeloma in comparison to that of myelodysplastic syndrome. Ann Hematol 85:869–871 doi:10.1007/s00277-006-0178-1 PubMedCrossRefGoogle Scholar
  18. 18.
    Loken MR, van de Loosdrecht A, Ogata K, Orfao A, Wells DA (2008) Flow cytometry in myelodysplastic syndromes: report from a working conference. Leuk Res 32:5–17 doi:10.1016/j.leukres.2007.04.020 PubMedCrossRefGoogle Scholar
  19. 19.
    Kern W, Haferlach C, Schnittger S, Haferlach T (2008) Dysplastic features detected by multiparameter flow cytometry in patients with MDS. Onkologie 31(S4):499Google Scholar
  20. 20.
    van de Loosdrecht AA, Westers TM, Westra AH et al (2008) Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry. Blood 111:1067–1077 doi:10.1182/blood-2007-07-098764 PubMedCrossRefGoogle Scholar
  21. 21.
    Greenberg P, Cox C, LeBeau MM et al (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079–2088PubMedGoogle Scholar
  22. 22.
    Germing U, Hildebrandt B, Pfeilstocker M et al (2005) Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS). Leukemia 19:2223–2231 doi:10.1038/sj.leu.2403963 PubMedCrossRefGoogle Scholar
  23. 23.
    Malcovati L, Germing U, Kuendgen A et al (2007) Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 25:3503–3510 doi:10.1200/JCO.2006.08.5696 PubMedCrossRefGoogle Scholar
  24. 24.
    Stauder R, Noesslinger T, Pfeilstöcker M et al (2008) Impact of age and comorbidity in myelodysplastic syndromes. J Natl Compr Canc Netw 6:927–934PubMedGoogle Scholar
  25. 25.
    Deschler B, Offermann B, Ihorst G et al (2008) Prospective multidimensional geriatric assessment in 210 patients >60 years with MDS/AML. Onkologie 31(S4):V495Google Scholar
  26. 26.
    Pelz D, Nachtkamp K, Kündgen A, Strupp C, Haas R, Germing U (2007) Influence of comorbidity factors on the prognosis of patients with myelodysplastic syndromes (MDS). Leuk Res 31(S1):15 doi:10.1016/S0145-2126(07)70053-X Google Scholar
  27. 27.
    Böhm A, Sperr WR, Leitner G et al (2008) Comorbidity predicts survival in myelodysplastic syndromes or secondary acute myeloid leukemia after allogeneic stem cell transplantation. Eur J Clin Invest 38:869–873CrossRefGoogle Scholar
  28. 28.
    Platzbecker U, Bornhäuser M, Germing U et al (2008) Red blood cell transfusion dependence and outcome after allogeneic peripheral blood stem cell transplantation in patients with de novo myelodysplastic syndrome (MDS). Biol Blood Marrow Transplant 14:1217–1225 doi:10.1016/j.bbmt.2008.08.006 PubMedCrossRefGoogle Scholar
  29. 29.
    Pitako JA, Haas PS, Van den Bosch J et al (2005) Quantification of outpatient management and hospitalization of patients with high-risk myelodysplastic syndrome treated with low-dose decitabine. Ann Hematol 84(S13):25–31 doi:10.1007/s00277-005-0007-y PubMedCrossRefGoogle Scholar
  30. 30.
    Kantarjian H, Issa JP, Rosenfeld CS et al (2006) Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 106:1794–1803 doi:10.1002/cncr.21792 PubMedCrossRefGoogle Scholar
  31. 31.
    Silvermann LR, Demakos EP, Peterson BL et al (2002) Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol 20:2429–2440 doi:10.1200/JCO.2002.04.117 CrossRefGoogle Scholar
  32. 32.
    Park S, Grabar S, Kelaidi C et al (2008) Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood 111:574–582 doi:10.1182/blood-2007-06-096370 PubMedCrossRefGoogle Scholar
  33. 33.
    Stadler M, Germing U, Kliche KO et al (2004) A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes. Leukemia 18:460–465 doi:10.1038/sj.leu.2403239 PubMedCrossRefGoogle Scholar
  34. 34.
    Nachtkamp K, Kündgen A, Strupp C, Gattermann N, Giagounidis A, Haas R, Germing U et al (2007) Influence of different treatment strategies on the prognosis of patients with MDS. Leuk Res 31(S1):14 doi:10.1016/S0145-2126(07)70052-8 Google Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Peter Valent
    • 1
  • Wolf-Karsten Hofmann
    • 2
  • Guntram Büsche
    • 3
  • Karl Sotlar
    • 4
  • Hans-Peter Horny
    • 5
  • Detlef Haase
    • 6
  • Torsten Haferlach
    • 7
  • Wolfgang Kern
    • 7
  • Peter Bettelheim
    • 8
  • Christian Baumgartner
    • 1
  • Wolfgang R. Sperr
    • 1
  • Thomas Nösslinger
    • 9
  • Friedrich Wimazal
    • 1
  • Aristoteles A. Giagounidis
    • 10
  • Michael Lübbert
    • 11
  • Otto Krieger
    • 12
  • Hans-Jochem Kolb
    • 13
  • Reinhard Stauder
    • 14
  • Michael Pfeilstöcker
    • 9
  • Norbert Gattermann
    • 15
  • Christa Fonatsch
    • 16
  • Carlo Aul
    • 10
  • Ulrich Germing
    • 15
  1. 1.Department of Internal Medicine I, Division of Hematology & HemostaseologyMedical University of ViennaViennaAustria
  2. 2.Department of Hematology, Oncology and Transfusion MedicineCharité University HospitalBerlinGermany
  3. 3.Institute of PathologyMedizinische Hochschule HannoverHannoverGermany
  4. 4.Institute of PathologyLudwig-Maximilians-Universität MünchenMünchenGermany
  5. 5.Klinikum Ansbach, Institute of PathologyAnsbachGermany
  6. 6.Department of Hematology and OncologyGeorg-August-UniversityGöttingenGermany
  7. 7.MLL Munich Leukemia LaboratoryMunichGermany
  8. 8.Institute for Laboratory MedicineOtto Wagner Hospital ViennaViennaAustria
  9. 9.Ludwig-Boltzmann Institute for Leukemia Research and HematologyHanusch HospitalViennaAustria
  10. 10.Medizinische Klinik IISt. Johannes Hospital DuisburgDuisburgGermany
  11. 11.Division of Hematology/Oncology, Department of MedicineUniversity of FreiburgFreiburgGermany
  12. 12.First Department of Internal MedicineElisabethinen HospitalLinzAustria
  13. 13.Department of Medicine IIIUniversity of Munich, GSF-National Research Centre for Environment and HealthMunichGermany
  14. 14.Division of Hematology and OncologyInnsbruck Medical UniversityInnsbruckAustria
  15. 15.Department of Hematology Oncology and Clinical ImmunologyHeinrich-Heine-UniversityDüsseldorfGermany
  16. 16.Department of Medical GeneticsMedical University of ViennaViennaAustria

Personalised recommendations